CHRM4 and early-onset autosomal dominant Alzheimer disease: This compound favoring muscarinicM2R and M4R may serve as a new lead structurefor further structural modifications to develop a novel class of selectiveM2R antagonists useful in the treatment of cognition deficitdiseases such as Alzheimer’s disease, schizophrenia, or CNSlearning disorders, such as autism or attention deficit disorder.